MedTrace Logo

Effects of Chinese Medicine on Early Pregnant Women

NCT04848571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2025-06-17

No results posted yet for this study

Summary

From April 2021 to December 2021, 45 pregnant women who received intro fertilization-embyro transfer (IVF-ET) were recuited. According to their own wishes, 28 of them took Chinese medicine from the 2nd week after embryo transfer (intervention group), while the remaining 17 did not intake Chinese medicine (control group). Blood and feces samples were collected in the early morning of the 4th week after embryo transfer to detect 16S DNA sequences in feces, plasma metabolites, and whole blood transcriptomics.

Conditions

  • Pregnant Women

Interventions

COMBINATION_PRODUCT

Fetal Protection Pill

A Chinese medicine used in pregnant women for fetal protection, including mainly Rehmannia glutinosa.

Sponsors & Collaborators

  • Shanghai Institute of Palnned parenthood research

    collaborator UNKNOWN

  • Shanghai Meiji Health Science and Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Enuo Liu, Dr. · Shanghai Institute of Planned Parenthood Research

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2021-11-01
Completion
2021-11-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04848571 on ClinicalTrials.gov